Actinium Pharmaceuticals - Receives Two Canadian Patent Allowances For Actimab-A And Iomab-Act Programs
Summary
Actinium Pharmaceuticals says it received two Canadian patent allowances covering its Actimab-A and Iomab-Act programs. The update strengthens the company’s intellectual property position in Canada for these therapeutic assets. No financing, acquisition, or product release is mentioned in the article. The item matters to readers tracking pharma companies and life sciences-focused software and industry developments.
Classifications
industries
No industries detected
applications
No applications detected
AskAI Classifications
Labels
No AI classifications detected